Autres langues Grand Pharmaceutical Group Limited OTC Markets

Actions

CGPHF

BMG210A71016

Produits pharmaceutiques

Temps Différé OTC Markets			Varia. 5j.	Varia. 1 janv.
- ^USD	-.--%		-.--%	-

26/08	Grand Pharmaceutical Group Limited publie ses résultats pour le semestre clos le 30 juin 2026	CI
10/08	Le candidat diagnostic de Grand Pharma contre le cancer obtient le statut "Fast Track" de la FDA ; l'action bondit de 5 %	MT

Autres langues

26/08	Grand Pharmaceutical Group Limited Reports Earnings Results for the Half Year Ended June 30, 2026
10/08	Grand Pharma's Cancer Diagnostic Candidate Gets FDA Fast Track Status; Shares Jump 5%
09/08	Grand Pharmaceutical Group Limited Receives Fast Track Designation from FDA for GPN01530-2 and Provides Updates on Nuclear Medicine Product Pipeline
23/07	Grand Pharma Enrolls, Doses First Patient in Depression Drug Candidate Trial
23/07	Grand Pharmaceutical Group Limited Announces First Patient Enrolled and Dosed in the Phase Iiiclinical Trial
05/06	Grand Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2025
14/04	Grand Pharmaceutical Says Liver Cancer Treatment Reaches Clinical Endpoint
13/04	Grand Pharmaceutical says SIR-Spheres Y-90 microsphere injection US HCC study reaches clinical endpoint
13/04	Grand Pharmaceutical Group Limited Announces Clinical Study Results and Product Pipeline Updates
09/04	Chinese business hired lobbying firm with ties to Don Jr, then scored a win in Washington
08/04	Grand Pharmaceutical Group Limited Establishes Strategic Partnership with the University of Hong Kong
27/03	Grand Pharmaceutical Group's 2025 Profit Falls Even as Revenue Jumps Over 5%
26/03	Grand Pharmaceutical Group Limited Reports Earnings Results for the Full Year Ended December 31, 2025
26/03	Grand Pharmaceutical Group posts FY revenue HKD 12,283.27 million
26/03	Grand Pharmaceutical Group Limited announces Annual dividend, payable on June 30, 2026
25/03	Grand Pharmaceutical Group says NMPA approves GPN01020 for phase II clinical trial
25/03	Grand Pharmaceutical Group Limited Announces Approval To Conduct Phase II Clinical Trial For Innovative Traditional Chinese Medicine GPN01020
23/03	Grand Pharmaceutical Group Forecasts Lower Profit For 2025; TP-03 Approved in China
22/03	Grand Pharmaceutical Group Limited Announces Approval of Global Innovative Product TP03 for Treatment of Demodex Blepharitis in China
20/03	Grand Pharmaceutical expects FY profit attributable HK$1.20 bln-HK$1.25 bln
20/03	Grand Pharmaceutical Group Limited Provides Earnings Guidance for the Year Ended December 31, 2025
19/03	Grand Pharmaceutical's unit enters into facility agreement for term loan facility of HK$0.8 billion
19/03	Grand Pharmaceutical Group Limited' Subsidiary China Grand Pharmaceutical (HK) Limited Enters into A Facility Agreement
19/01	Grand Pharmaceutical Group Limited Announces National Medical Products Administration of the People's Republic of China Accepts New Drug Application of Tlx591-Cdx
19/01	Grand Pharmaceutical Says Imaging Agent Accepted For Chinese Regulatory Review